I agree that this site is using cookies. You can find further informations here.
X
Clayden, Polly
59  results:
Search for persons X
?
1

Final 192-Week Efficacy and Safety Results of the ADVANCE T..:

Sokhela, Simiso ; Venter, Willem D F ; Bosch, Bronwyn...
Open Forum Infectious Diseases.  11 (2024)  3 - p. , 2024
Link: https://doi.org/10.1093/..
 
?
2

Engaging the community of women living with HIV to tailor a..:

Clayden, Polly ; Zech, Jennifer M. ; Irvine, Cadi..
Journal of the International AIDS Society.  25 (2022)  S2 - p. , 2022
Link: https://doi.org/10.1002/..
 
?
3

Accelerating investigation of new HIV drugs in pregnancy: a..:

Penazzato, Martina ; Lockman, Shahin ; Colbers, Angela...
Journal of the International AIDS Society.  25 (2022)  S2 - p. , 2022
Link: https://doi.org/10.1002/..
 
?
4

What Clinicians Need to Know About the Development of Long-..:

Flexner, Charles ; Thomas, David L ; Clayden, Polly.
Clinical Infectious Diseases.  75 (2022)  Supplement_4 - p. S487-S489 , 2022
Link: https://doi.org/10.1093/..
 
?
5

72 weeks post-partum follow-up of dolutegravir versus efavi..:

Malaba, Thokozile R ; Nakatudde, Irene ; Kintu, Kenneth...
The Lancet HIV.  9 (2022)  8 - p. e534-e543 , 2022
Link: https://doi.org/10.1016/..
 
?
6

Clinical and population‐based study design considerations t..:

Brummel, Sean S. ; Stringer, Jeff ; Mills, Ed...
Journal of the International AIDS Society.  25 (2022)  S2 - p. , 2022
Link: https://doi.org/10.1002/..
 
?
7

Impact of long-acting therapies on the global HIV epidemic:

Chandiwana, Nomathemba C. ; Serenata, Celicia M. ; Owen, Andrew...
AIDS.  35 (2021)  Supplement 2 - p. S137-S143 , 2021
Link: https://doi.org/10.1097/..
 
?
8

What we have learned from antiretroviral treatment optimiza..:

Venter, W.D. Francois ; Serenata, Celicia ; Vitoria, Marco...
AIDS.  35 (2021)  Supplement 2 - p. S113-S115 , 2021
Link: https://doi.org/10.1097/..
 
?
9

Weight gain stopping/switch rules for antiretroviral clinic..:

Venter, W.D. Francois ; Sokhela, Simiso ; Calmy, Alexandra...
AIDS.  35 (2021)  Supplement 2 - p. S183-S188 , 2021
Link: https://doi.org/10.1097/..
 
?
10

Phase 3 trials of new antiretrovirals are not representativ..:

Pepperrell, Toby ; Hill, Andrew ; Moorhouse, Michelle...
Journal of Virus Eradication.  6 (2020)  2 - p. 70-73 , 2020
Link: https://doi.org/10.1016/..
 
?
11

Pharmacokinetics of antiretroviral and tuberculosis drugs i..:

Jacobs, Tom G ; Svensson, Elin M ; Musiime, Victor...
Journal of Antimicrobial Chemotherapy.  75 (2020)  12 - p. 3433-3457 , 2020
Link: https://doi.org/10.1093/..
 
?
12

Risks and benefits of dolutegravir-based antiretroviral dru..:

Phillips, Andrew N ; Venter, Francois ; Havlir, Diane...
The Lancet HIV.  6 (2019)  2 - p. e116-e127 , 2019
Link: https://doi.org/10.1016/..
 
?
13

Long-acting or extended-release antiretroviral products for..:

Nachman, Sharon ; Townsend, Claire L ; Abrams, Elaine J...
The Lancet HIV.  6 (2019)  8 - p. e552-e558 , 2019
Link: https://doi.org/10.1016/..
 
?
14

Inclusion of pregnant women in antiretroviral drug research..:

Fairlie, Lee ; Waitt, Catriona ; Lockman, Shahin...
Journal of the International AIDS Society.  22 (2019)  9 - p. , 2019
Link: https://doi.org/10.1002/..
 
?
15

Optimizing responses to drug safety signals in pregnancy: t..:

Mofenson, Lynne M ; Pozniak, Anton L ; Wambui, Jacque...
Journal of the International AIDS Society.  22 (2019)  7 - p. , 2019
Link: https://doi.org/10.1002/..
 
1-15